Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

December 18, 2023

https://www.globenewswire.com/news-release/2023/12/18/2797670/29236/en/Cara-Therapeutics-Announces-Outcome-from-Dose-Finding-Part-A-of-KIND-1-Study-Evaluating-Oral-Difelikefalin-for-Moderate-to-Severe-Pruritus-in-Patients-with-Atopic-Dermatitis.html

– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis –

Read more at globenewswire.com

Related news for (CARA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.